ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OLMA Olema Pharmaceuticals Inc

11.32
0.12 (1.07%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 499,221
Bid Price 10.77
Ask Price 11.75
News -
Day High 11.50

Low
3.00

52 Week Range

High
17.7911

Day Low 10.79
Company Name Stock Ticker Symbol Market Type
Olema Pharmaceuticals Inc OLMA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.12 1.07% 11.32 20:00:00
Open Price Low Price High Price Close Price Prev Close
11.21 10.79 11.50 11.32 11.20
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,805 499,221 $ 11.22 $ 5,603,729 - 3.00 - 17.7911
Last Trade Time Type Quantity Stock Price Currency
19:29:44 7 $ 10.86 USD

Olema Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
632.95M 55.91M - 0 -104.79M -1.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Olema Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No OLMA Message Board. Create One! See More Posts on OLMA Message Board See More Message Board Posts

Historical OLMA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.8211.8510.7811.22712,149-0.50-4.23%
1 Month13.1215.3210.6512.171,120,680-1.80-13.72%
3 Months13.6816.77510.6512.77831,995-2.36-17.25%
6 Months13.0817.79119.9613.05798,932-1.76-13.46%
1 Year3.4417.79113.0011.71559,9597.88229.07%
3 Years30.6536.702.0011.69420,791-19.33-63.07%
5 Years47.0060.272.0013.12393,951-35.68-75.91%

Olema Pharmaceuticals Description

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.

Your Recent History

Delayed Upgrade Clock